异长春花碱为主的联合方案治疗晚期非小细胞肺癌的临床研究  

Clinical study of the treatment of Advanced non - small cell lung cancer mainly by navelibine combined with chemotherapy

作　　者：姜洪斌[1] 郭映华[1] 徐建明[2] 

机构地区：[1]上海市肺科医院,上海200433 [2]第二军医大学化学教研室,上海200433

出　　处：《临床肿瘤学杂志》2001年第4期334-336,共3页Chinese Clinical Oncology

摘　　要：目的:观察异长春花碱(ＮＶＢ)加丝裂霉素(ＭＭＣ)、顺铂(ＤＤＰ)联合化疗治疗晚期非小细胞肺癌的疗效和毒副作用。方法:５２例肺癌中,男性３７例,女性１５例;初治３８例,复治１４例;病理为鳞癌２９例,腺癌１６例,腺鳞癌４例,未分类３例;Ⅲｂ期３３例,Ⅳ期１９例。化疗方案为ＭＮＰ,即ＭＭＣ６ｍｇ/ｍ２Ｄ１天静注,ＮＶＢ２５ｍｇ/ｍ２Ｄ１、８天静注,ＤＤＰ３０ｍｇ/ｍ２Ｄ１-３天静注。每周期间隔２８天,均采用二周期以上评价疗效。结果:完全缓解１例,部分缓解２８例,总有效率５５．８%;中位缓解期５．２个月,中位生存期１１．７个月;主要毒副反应为骨髓抑制。结论:以ＮＶＢ为主的联合化疗对晚期非小细胞肺癌有较好的疗效和可耐受的毒副作用。ve: To observe the therapeutic effect and toxic side - effects of the combination chemotherapy with navelbine plus mitomycin c and cisplatin in the treatment of non - small cell lung cancer(NSCLC). Methods: There were totally 52 NSCLC patients, in which male for 37 cases, female for 15 cases. Primary treatment for 38 cases, return treatment for 14 cases. The pathology revealed 29 cases of squamous cell carcinoma, 16 cases of adenocarcinoma, 4 cases of adenosquamous carcinoma, and 3 cases of Unclassified carcinoma. 33 cases had stage Ⅲb disease and 19 had stage Ⅳ . MNP chemotherapeutic regimen: MMC 6mg/m D1, intravenous injection for 1 day, NVB25mg/m2, D1,8, intravenous injection for 2 days, DDP30mg/m2, D1-3, intravenous injection, con-tinuously for 3 days, repeated every 28 days. The evaluation of therapeutic effect was more than 2 cycles. Results:Complete response was observed in 1 patient and partial response was observed in 28 patients with an overall response rate of 55. 8% . The median response duration was 5.2 months and the median survival period was 11.7 months. The principal toxic side- effect was inhibition of bone marrow. Conclusions: Advanced non - small cell lung cancer treated mainly by MNP regimen shows a better therapeutic effect, and toxic side- effects are tolerant.

关 键 词：非小细胞肺癌 药物疗法 异长春花碱 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]